AXP-1275 / Axikin - LARVOL DELTA

The Effects of a CCR3 Inhibitor, AXP1275, on Allergen-Induced Airway Responses in Adults with Mild-to-Moderate Atopic Asthma. (PubMed, Clin Exp Allergy) - "AXP1275 50 mg administered daily was safe and well tolerated, and there was no difference in the type, severity, or frequency of treatment-emergent adverse events in subjects while receiving AXP1275 compared to placebo. AXP1275 increased the methacholine PC20 however the low and variable exposure to APX1275 over a short treatment period may have contributed to poor efficacy on other outcomes."

Clinical • Journal